Japan’s Wakamoto, GSK Arm Team To Co-Market Botox
This article was originally published in PharmAsia News
Executive SummaryJapan's Wakamoto Pharmaceutical and U.K.-based GlaxoSmithKline's Japanese unit have reached a co-marketing agreement for GSK's Botox (botulinum toxin type A) beginning July 6. U.S.-based Allergan owns Botox, but GSK has the Japanese and Chinese rights to develop the drug, which has both cosmetic and medical uses, such as treating facial muscle spasms and eye blinking. With Wakamoto, GSK seeks to promote the drug for eye-related therapy. (Click here for more - a subscription may be required
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.